GLP-1 Insurance Coverage in 2026: Does Your Plan Pay for Weight Loss?

Does Insurance Cover GLP-1s for Weight Loss?

Some plans do, but most still don’t. GLP-1 insurance coverage for weight loss depends on who sponsors your plan, and the numbers are low.

In the KFF 2025 Employer Health Benefits Survey, 19% of firms with 200 or more workers covered GLP-1s for weight loss. Size matters a lot: 16% of firms with 200 to 999 workers did, compared with 43% of firms with 5,000 or more, up from 28% a year earlier.

A July 2026 IFEBP pulse survey found the same picture. 36% of employers covered GLP-1s for both diabetes and weight loss, the same share as in 2025. Another 60% covered them for diabetes only.

Cost is the reason. In KFF’s survey, 59% of the largest firms said use was higher than expected, and 66% said GLP-1s had a significant impact on their drug spending. Only 1% of firms without coverage were very likely to add it within a year.

Why Does Your Diagnosis Matter More Than the Drug?

Plans pay for a drug for a specific use, so GLP-1 insurance coverage often hinges on your diagnosis. The same molecule can be covered for one condition and excluded for another.

Many plans exclude drugs used “for weight loss,” but they don’t exclude treatment for diabetes, heart disease or sleep apnea. Each new FDA approval gives your prescriber another route. The table shows the approved uses for the main GLP-1s, as of September 2026.

Prediabetes, PCOS and insulin resistance are not FDA-approved uses for any of these drugs. A plan can still cover a weight-management GLP-1 if your BMI and health conditions meet the label, which means a BMI of 30 or more, or 27 or more with a weight-related condition.

Do Employer Plans Cover GLP-1s in 2026?

A minority do, and more of them now attach conditions. Large employers are the most likely to cover GLP-1s for weight loss, and small employers the least.

In the IFEBP survey, 45% of employers covered GLP-1s for other FDA-approved conditions such as sleep apnea and heart disease. Some steer workers elsewhere instead: 27% pointed employees to direct-to-consumer programs, and 21% encouraged using an FSA, HSA or HRA. GLP-1s made up 11.4% of employers’ drug claims in 2026, up from 6.9% in 2023.

Extra rules are spreading. KFF found that 34% of firms covering GLP-1s for weight loss required something more in 2025, such as meeting a dietitian or case manager or joining a lifestyle program. That was up from 10% in 2024.

Which Brand Does Your Plan Prefer?

Your pharmacy benefit manager (PBM) often decides which brand your plan pays for. CVS Caremark, one of the largest, dropped Zepbound from its standard formularies on July 1, 2025 and made Wegovy its preferred GLP-1.

That changes on October 1, 2026. CVS Health said on May 28, 2026 that Zepbound would return as a co-preferred option alongside Wegovy on its standard commercial formulary. It also removed its new-to-market block on Foundayo on June 1, 2026. Your employer can still choose a different formulary, so check your own plan.

Does Medicaid Cover GLP-1s for Weight Loss?

Only in a minority of states. KFF counted 13 state Medicaid programs that covered GLP-1s for obesity under fee-for-service as of January 2026.

The list keeps shrinking. California, New Hampshire, Pennsylvania and South Carolina dropped obesity coverage after October 2025. North Carolina dropped it in October 2025 and brought it back in December.

Medicaid programs do cover GLP-1s for type 2 diabetes, usually with prior authorization. The federal weight-loss exclusion only lets states leave out drugs used for weight loss.

CMS also offered states a new option. Under its BALANCE Model, states could start covering GLP-1s at negotiated prices between May 1, 2026 and January 1, 2027. Ask your state Medicaid office whether it joined.

Does Medicare Cover GLP-1s for Weight Loss?

Not through Part D, but a temporary program fills part of the gap. Medicare law bars Part D plans from covering drugs used for weight loss.

Since July 1, 2026, the Medicare GLP-1 Bridge lets eligible Part D enrollees get Wegovy, Foundayo or the Zepbound KwikPen for $50 per monthly fill, through December 31, 2027. You must meet BMI rules and can’t have type 2 diabetes, moderate-to-severe sleep apnea or MASH, because Part D already covers GLP-1s for those.

Part D can also cover Wegovy prescribed to lower heart risk, Zepbound for sleep apnea and GLP-1s for diabetes, with your plan’s normal copays.

Do ACA Marketplace Plans Cover GLP-1s?

It depends on the insurer and the state. Marketplace plans set their own drug lists, and GLP-1 insurance coverage for weight loss varies from plan to plan.

Before you pick a plan, open its formulary and search for Wegovy, Zepbound and Foundayo. Look for the tier, a “PA” (prior authorization) flag, “ST” (step therapy) and quantity limits. If the formulary lists a drug only for diabetes, assume weight-loss use isn’t covered and call to confirm.

Plans can change their formularies each year. If you rely on a GLP-1, recheck every open enrollment.

What Does Prior Authorization for a GLP-1 Require?

Expect your plan to ask for proof that you meet the FDA label and its own extra rules. Your prescriber submits the request, but the records come from you and your chart.

Most requests need the same core documents:

• Your current weight, height and BMI, dated and recorded in your chart.
• Diagnosis codes for weight-related conditions, such as high blood pressure or high cholesterol.
• Records for a second approved use, if you have one: a sleep study for sleep apnea, cardiology records for heart disease, or liver test results for MASH.
• Proof of a diet, exercise or lifestyle program, if your plan requires one.
• A list of weight-loss drugs you’ve tried before, if the plan uses step therapy.

Ask how long an approval lasts and what you must show to renew it. Some plans want a minimum amount of weight loss at renewal, and the rules differ by plan.

How Do You Check Your GLP-1 Insurance Coverage?

Check the plan’s formulary first, then call to confirm. Lilly and Novo Nordisk also run coverage checkers on their savings pages for Zepbound and Wegovy.

If you call, ask these questions and write down the date and the rep’s name:

1. Is Zepbound, Wegovy or Foundayo covered for chronic weight management under my plan?
2. Is it covered for sleep apnea, heart disease or MASH if my doctor documents that diagnosis?
3. What are the prior authorization criteria, and can you send them to me?
4. What will I pay per fill once it’s approved?
5. How long does an approval last, and what’s needed to renew it?

What If Your Insurance Denies a GLP-1?

Read the denial letter, fix what’s missing and appeal. Many GLP-1 insurance coverage denials come from paperwork gaps rather than a plan-wide exclusion.

1. Find the reason. The letter should say whether the drug is excluded, the criteria weren’t met or records were missing.
2. Ask your prescriber to resubmit with the missing records, or to request a peer-to-peer call with the plan’s reviewer.
3. If the drug is off the formulary but medically necessary, ask for a formulary exception.
4. File an internal appeal. HealthCare.gov says you must file within 180 days of the denial notice. Urgent cases get faster decisions.
5. If the plan still says no, ask for an external review. An independent reviewer decides, and a standard review takes no more than 45 days after it’s received.

A plan-wide exclusion for weight-loss drugs is harder to overturn. In that case, a second approved diagnosis or a different payment route is usually your better option.

What Are Your Options If Insurance Won’t Pay?

You can still get an FDA-approved GLP-1 at the makers’ cash prices, and some options cost less than people expect. Here’s what each route costs as of September 2026.

Savings cards exclude Medicare, Medicaid, TRICARE and the VA. HSA and FSA money can often pay for prescribed drugs, but check with your plan first.

Compounded semaglutide and tirzepatide cost less, but they’re not FDA-approved and insurance doesn’t cover them. See what’s legal now for compounded GLP-1s before you choose that route.